MiMedx: How a Delinquent 10-K Became a Delisting and a Court-Ordered Annual Meeting

Most compliance calendars die quietly. MiMedx Group's died in public, in stages, over eighteen months, and the sequence is worth studying because every stage followed mechanically from the one before it. A revenue-recognition problem became a filing delinquency; the delinquency exhausted the exchange's maximum cure period; the delisting stranded the stock on the OTC market; and the missed annual meetings put the company in Delaware Chancery on the wrong end of a DGCL § 211 order. Nothing in that chain was discretionary. Once the first deadline broke, every downstream deadline broke on schedule.

What actually happened at MiMedx?

MiMedx was a Marietta, Georgia regenerative-medicine company, amniotic tissue grafts, a market value that had run to roughly $2 billion at its peak, and a Nasdaq listing. In February 2018, the company announced it would delay its 2017 Form 10-K amid an audit committee investigation into revenue recognition, following short-seller and whistleblower allegations of channel-stuffing through its distributor network.

The investigation kept widening. In June 2018, the company announced it would restate its financial statements, ultimately covering fiscal 2012 through 2016 plus interim 2017 periods, five years of numbers. The board ousted longtime CEO Parker "Pete" Petit and COO William Taylor in mid-2018 (a departure initially styled as retirement). The Department of Justice and SEC investigations that followed ended with a federal jury convicting Petit of securities fraud in November 2020.

While the restatement ground on, the company filed nothing. No 10-K, no 10-Qs, and, critically for this teardown, no proxy statement and no annual meeting.

Why did Nasdaq's clock run out?

Because Nasdaq's delinquency framework has a hard ceiling, and MiMedx hit it.

Under Listing Rule 5250(c)(1), a delinquent periodic filing starts a cure process: Rule 5810(c)(2)(F), that can stretch, between staff exceptions and a Hearings Panel, to a maximum of 360 calendar days from the due date of the first delinquent filing. MiMedx's 2017 10-K was due in early 2018; the Panel's outside compliance date was February 25, 2019. On October 31, 2018, MiMedx submitted a progress report telling the Panel that management now believed revenue recognition for all of the company's sales needed reassessment, meaning the restatement could not be completed by the deadline.

The Panel did the only thing the rule left it: on November 7, 2018, MiMedx received a delisting determination, and trading was suspended at the open on November 8. The stock moved to OTC quotation under the same ticker. Note the mechanics, the Panel did not "decide" to delist a company making good-faith progress; the 360-day ceiling decided, months before the formal notice. Any company inside this framework can compute its own drop-dead date on day one. Most never do. That arithmetic, the cascading deadlines from one broken filing, is exactly what the free Annual Meeting & Proxy Timeline tool is built to surface while the dates are still curable.

How does a company end up court-ordered to hold its own annual meeting?

By forgetting that the stockholder franchise runs on a separate clock that no restatement pauses.

MiMedx held no annual meeting in 2018. Its position was the intuitive one: with five years of financials unreliable and no current 10-K, shareholders could not make an informed election, so the meeting should wait for the restatement. Delaware law flatly rejects that logic. Under DGCL § 211(c), once 13 months pass without an annual meeting, any stockholder may petition the Court of Chancery to summarily order one, and Delaware courts have held for decades that delinquent financials are no defense to the franchise right.

A stockholder did exactly that. The Court of Chancery ordered MiMedx to hold its overdue 2018 annual meeting on June 17, 2019; the company resisted and said it would appeal, and press releases were still contesting the meeting the day before it occurred. The meeting went forward anyway, as a full-blown proxy contest, with the ousted founder Petit soliciting against the reconstituted board via his own proxy card. The company that had wanted no meeting at all got the most expensive kind there is: a court-ordered, contested one, run on a schedule it did not choose, while still unable to hand shareholders an audited annual report.

MiMedx completed its restatement and resumed current filing in 2019 and returned to Nasdaq in 2020, roughly two years of OTC trading, depressed institutional ownership, and litigation later.

What should a small-cap CFO take from this?

Four transferable lessons, none of which require MiMedx-scale misconduct to matter:

1. The 360-day ceiling is computable on day one. The moment a 10-K slips, calendar the outer boundary of Rule 5810(c)(2)(F) and treat it as a covenant. MiMedx's fatal disclosure, that the restatement scope had expanded past the deadline, surprised the market, but the deadline itself was never a surprise.
2. The § 211 clock runs independently. Filing delinquency, restatement, even an active investigation: none of it tolls the 13-month meeting requirement. A company in a filing crisis should be planning its annual meeting around the crisis, not deferring it, because a stockholder petition transfers scheduling control to the court.
3. Delinquencies compound. No 10-K means no Rule 14a-3-compliant annual report, which blocks a clean proxy, which blocks the meeting, which ripens the § 211 claim. One broken deadline is never one broken deadline.
4. Governance vacuums attract contests. The court-ordered meeting became the venue for Petit's counterattack. Skipped meetings do not defer shareholder conflict; they concentrate it.

The entire MiMedx sequence, broker search to record date to proxy to meeting to 8-K, is a dependency chain that the free Annual Meeting & Proxy Timeline tool lays out in one screen. The companies that end up in Chancery are rarely the ones that built the chain and missed a link; they are the ones that never built it.

FAQ

Why was MiMedx delisted from Nasdaq?

Delinquent SEC filings. Its restatement (fiscal 2012–2016 plus interim 2017) could not be completed within Nasdaq's maximum 360-day delinquency cure window; the delisting determination came November 7, 2018, with trading suspended November 8.

Who forced MiMedx to hold its annual meeting?

The Delaware Court of Chancery, on a stockholder petition under DGCL § 211(c), after the company went well past the 13-month statutory window. The court-ordered 2018 annual meeting was held June 17, 2019, over the company's objection.

Are delinquent financial statements a valid reason to postpone an annual meeting?

No. Delaware courts have consistently ordered meetings at companies with unfiled or unreliable financials, the shareholder franchise under § 211 does not depend on audited numbers being available.

Did MiMedx survive the delisting?

As a company, yes, it completed the restatement, resumed filing, and relisted on a national exchange in 2020. But it absorbed roughly two years of OTC trading, a court-ordered proxy contest, and executive criminal convictions along the way.

Facts as summarized from public filings, enforcement orders, and press reports. This case study is commentary on public information for educational purposes; it is not investment, legal, or accounting advice, and Unfolding Values had no engagement with any company discussed.